Biogen Inc.
BIIB Stock News
Latest BIIB news
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Zacks Investment Research · Mon, 21 Sep 2026 13:40:52 -0400
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
GlobeNewsWire · Thu, 17 Sep 2026 16:15:00 -0400
CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI® (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology (CJASN). The dedicated subgroup analysis was first presented at the 2025 Annual Meeting of the European Society of Paediatric Nephrology (ESPN).
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease
GlobeNewsWire · Wed, 16 Sep 2026 02:00:00 -0400
The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
MarketBeat · Tue, 15 Sep 2026 00:02:09 -0400
Biogen NASDAQ: BIIB is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quarter and said its recently acquired assets could help accelerate revenue growth.
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha · Mon, 14 Sep 2026 11:21:40 -0400
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology
MarketBeat · Sat, 12 Sep 2026 17:02:21 -0400
Biogen NASDAQ: BIIB executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth.
Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha · Wed, 09 Sep 2026 15:27:04 -0400
Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Market information is provided for research and visualization and is not investment advice.